{"protocolSection": {"identificationModule": {"nctId": "NCT01102140", "orgStudyIdInfo": {"id": "IMPROVEHF"}, "organization": {"fullName": "University of Michigan", "class": "OTHER"}, "briefTitle": "The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study", "officialTitle": "The Impact of Pomegranate (Punica Granatum) Polyphenol Extract on Oxidative Stress, Ventricular Remodeling and Endothelial Function in Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study", "acronym": "ImPrOVE"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "TERMINATED", "whyStopped": "Investigator left University of Michigan", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-07"}, "primaryCompletionDateStruct": {"date": "2013-05-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-05-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-12", "studyFirstSubmitQcDate": "2010-04-12", "studyFirstPostDateStruct": {"date": "2010-04-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-05-18", "resultsFirstSubmitQcDate": "2017-06-13", "resultsFirstPostDateStruct": {"date": "2017-07-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-06-13", "lastUpdatePostDateStruct": {"date": "2017-07-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Jennifer Cowger , MD, MS", "investigatorTitle": "Assistant Professor, study PI", "investigatorAffiliation": "University of Michigan"}, "leadSponsor": {"name": "Jennifer Cowger , MD, MS", "class": "OTHER"}, "collaborators": [{"name": "POM Wonderful LLC", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false}, "descriptionModule": {"briefSummary": "This blinded, controlled study will examine the impact of pomegranate polyphenol extract (POMx, from Pom Wonderful, LLC), 1000mg on cardiomyopathy in subjects with chronic renal insufficiency.", "detailedDescription": "Heart failure (HF) is a disease of great prevalence in the U.S. with an associated high morbidity and mortality. In individuals with concomitant chronic renal insufficiency (CRI), outcomes are even worse due to pharmaceutical under treatment and higher baseline levels of oxidative stress. Reactive oxygen species (ROS) are generated during mechanoenergetic uncoupling and can cause myocardial protein, lipid, and DNA damage, leading to the development of HF. One means of preventing the progression of HF may be through ROS reduction or an improvement in systemic or local oxidative stress handling. In this randomized, single blind placebo-controlled pilot study, we hypothesize that 12 weeks of treatment with oral pomegranate extract (POMx) will lead to a reduction in oxidative stress (as assessed by measuring thiobarbituric acid-reactive substances, F8-isoprostanes, and glutathione) in subjects (n=30) with cardiomyopathy (LVEF \u226440%) and CRI (GFR \\<60 ml/hr). Secondary aims include assessing the impact of POMx on myocardial remodeling and endothelial dysfunction by measuring serum collagen levels and asymmetric dimethylarginine, respectively. Findings from this study will serve as pilot data for a larger randomized trial of longer term POMx therapy in subjects with cardiomyopathy."}, "conditionsModule": {"conditions": ["Cardiomyopathy", "Heart Failure"], "keywords": ["Cardiomyopathy", "Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "The participant will either receive POMx or matching placebo (sugar pill)", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 20, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "POMx", "type": "ACTIVE_COMPARATOR", "description": "15 subjects will received 1000 mg of oral POMx for 12 weeks.", "interventionNames": ["Drug: POMx, pomegranate polyphenol extract"]}, {"label": "Control- sugar Pill", "type": "PLACEBO_COMPARATOR", "description": "15 subjects will receive a matching sugar pill for 12 weeks.", "interventionNames": ["Drug: Sugar Pill"]}], "interventions": [{"type": "DRUG", "name": "POMx, pomegranate polyphenol extract", "description": "1000 mg orally once daily.", "armGroupLabels": ["POMx"]}, {"type": "DRUG", "name": "Sugar Pill", "description": "Matching sugar pill", "armGroupLabels": ["Control- sugar Pill"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Thiobarbituric Reactive Substances (TBARS)", "description": "This is a serum marker of oxidative stress.", "timeFrame": "baseline and after 12 weeks"}], "secondaryOutcomes": [{"measure": "F-8 Isoprostanes", "description": "This is a serum marker of oxidative stress.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Procollagen Types I (PINP) and III (PIIINP)", "description": "This is a serum marker of collagen turnover (fibrosis/scar formation).", "timeFrame": "baseline and 12 weeks"}, {"measure": "Asymmetric Dimethylarginine (ADMA)", "description": "ADMA is a serum enzyme involved in metabolism of endothelium derived nitric oxide (NO). NO's has an important role in maintaining endothelial homeostasis. Elevated ADMA levels suggest impaired endothelial function.", "timeFrame": "baseline and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adult subjects (\u226521 years of age) with cardiomyopathy (ejection fraction \u226440%) of at least 1 year duration and CRI (GFR \\<60 cc/hr for at least 3 months) will be eligible for enrollment.\n* Subjects must have New York Heart Association (NYHA) functional class I-III symptoms and be on stable doses of HF evidence-based therapies (\u03b2-blocker, ACE inhibitor or ARBs, aldosterone inhibitor \\[if appropriate\\]) for at least 3 months or have a documented contraindication or intolerance to such therapy\n\nExclusion Criteria:\n\n* Subjects admitted to a hospital for acute myocardial infarction (defined as positive troponins) or HF exacerbation within the last 6 months will not be eligible for enrollment.\n* Subjects on warfarin or rosuvastatin will also be excluded.\n* Other exclusion criteria are as follows:\n\n  * HF that is deemed to be congenital or infiltrative in etiology\n  * the presence of a life-threatening illness with a projected survival \u22646 months; ongoing infection\n  * pregnancy\n  * inability to follow-up\n  * end-stage renal disease requiring dialysis\n  * renal transplant listing\n  * recent (within last 6 months) POMx use or intake \\>8 ounces daily of pomegranate juice\n  * known hypersensitivity to any fruit in the Punicaceae family\n  * connective tissue or collagen vascular disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jennifer C Matthews, MD, MS", "affiliation": "Univeristy of Michigan Health System", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Bertram Pitt, MD", "affiliation": "University of Michigan", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Michigan Health Systems", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "University of Michigan Health System", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "POMx", "description": "The POMx subjects received 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily."}, {"id": "FG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks.\n\nSugar Pill: Matching sugar pill"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Investigator terminated study", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "POMx", "description": "The POMx subjects received 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily."}, {"id": "BG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks.\n\nSugar Pill: Matching sugar pill"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "20"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "15"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57", "lowerLimit": "49", "upperLimit": "64"}, {"groupId": "BG001", "value": "58", "lowerLimit": "52", "upperLimit": "64"}, {"groupId": "BG002", "value": "57", "lowerLimit": "50", "upperLimit": "64"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "18"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "18"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "20"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Thiobarbituric Reactive Substances (TBARS)", "description": "This is a serum marker of oxidative stress.", "populationDescription": "Serum samples were obtained and frozen but never analyzed to obtain isoprostane values due to PI departure from study center prior to any batches being sent for analysis.", "reportingStatus": "POSTED", "timeFrame": "baseline and after 12 weeks", "groups": [{"id": "OG000", "title": "POMx", "description": "The POMx subjects received 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily."}, {"id": "OG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks.\n\nSugar Pill: Matching sugar pill"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "F-8 Isoprostanes", "description": "This is a serum marker of oxidative stress.", "populationDescription": "Serum samples were obtained and frozen but never analyzed to obtain isoprostane values due to PI departure from study center prior to any batches being sent for analysis", "reportingStatus": "POSTED", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "POMx", "description": "The POMx subjects received 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily."}, {"id": "OG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks.\n\nSugar Pill: Matching sugar pill"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Procollagen Types I (PINP) and III (PIIINP)", "description": "This is a serum marker of collagen turnover (fibrosis/scar formation).", "populationDescription": "Serum samples were obtained and frozen but never analyzed to obtain procollagen values due to PI departure from study center prior to any batches being sent for analysis", "reportingStatus": "POSTED", "timeFrame": "baseline and 12 weeks", "groups": [{"id": "OG000", "title": "POMx", "description": "The POMx subjects will receive 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily."}, {"id": "OG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks.\n\nSugar Pill: Matching sugar pill"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Asymmetric Dimethylarginine (ADMA)", "description": "ADMA is a serum enzyme involved in metabolism of endothelium derived nitric oxide (NO). NO's has an important role in maintaining endothelial homeostasis. Elevated ADMA levels suggest impaired endothelial function.", "populationDescription": "Serum samples were obtained and frozen but never analyzed to obtain ADMA values due to PI departure from study center prior to any batches being sent for analysis", "reportingStatus": "POSTED", "timeFrame": "baseline and 12 weeks", "groups": [{"id": "OG000", "title": "POMx", "description": "The POMx subjects received 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily."}, {"id": "OG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks. Sugar Pill: Matching sugar pill"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "POMx", "description": "15 subjects received 1000 mg of oral POMx for 12 weeks.\n\nPOMx, pomegranate polyphenol extract: 1000 mg orally once daily.", "deathsNumAffected": 0, "deathsNumAtRisk": 13, "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 0, "otherNumAtRisk": 13}, {"id": "EG001", "title": "Control- Sugar Pill", "description": "The control subjects received a matching sugar pill for 12 weeks.\n\nSugar Pill: Matching sugar pill", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 0, "otherNumAtRisk": 7}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Jennifer Cowger", "organization": "University of Michigan", "email": "jennifercowger@gmail.com", "phone": "7345464911"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000051437", "term": "Renal Insufficiency"}, {"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000007674", "term": "Kidney Diseases"}, {"id": "D000014570", "term": "Urologic Diseases"}, {"id": "D000052776", "term": "Female Urogenital Diseases"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000052801", "term": "Male Urogenital Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M22079", "name": "Ventricular Remodeling", "relevance": "LOW"}, {"id": "M26718", "name": "Renal Insufficiency", "asFound": "Renal Insufficiency", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M10698", "name": "Kidney Diseases", "relevance": "LOW"}, {"id": "M17319", "name": "Urologic Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "M27095", "name": "Male Urogenital Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "T257", "name": "Pomegranate", "asFound": "Atypical", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "HB", "name": "Herbal and Botanical"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}